Ftse Mib
34.490,71
0,07%
DAX
18.693,37
0,04%
S&P 500
5.304,72
0,70%
NASDAQ
16.920,79
1,10%
Bitcoin
68.929,75
-0,49%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Seres Therapeutics Inc (MCRB) Seres Therapeutics Inc (MCRB) Notizie

MCRB

Seres Therapeutics (MCRB)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MCRB
DataOraFonteTitoloSimboloCompagnia
18/05/202402:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
08/05/202416:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MCRBSeres Therapeutics Inc
08/05/202413:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
08/05/202413:00Business WireSeres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:MCRBSeres Therapeutics Inc
06/05/202422:01Business WireSeres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MCRBSeres Therapeutics Inc
06/05/202415:30Business WireSeres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024NASDAQ:MCRBSeres Therapeutics Inc
09/04/202413:00Business WireSeres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCTNASDAQ:MCRBSeres Therapeutics Inc
05/03/202416:18Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:MCRBSeres Therapeutics Inc
05/03/202416:13Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MCRBSeres Therapeutics Inc
05/03/202413:00Business WireSeres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:MCRBSeres Therapeutics Inc
05/03/202412:05IH Market NewsU.S. Futures Dip, Crude Oil FluctuatesNASDAQ:MCRBSeres Therapeutics Inc
28/02/202413:00Business WireSeres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024NASDAQ:MCRBSeres Therapeutics Inc
27/02/202413:00Business WireSeres Therapeutics to Participate in Cowen 44th Annual Healthcare ConferenceNASDAQ:MCRBSeres Therapeutics Inc
26/02/202413:00Business WireSeres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David ArkowitzNASDAQ:MCRBSeres Therapeutics Inc
23/02/202422:05Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:MCRBSeres Therapeutics Inc
09/01/202414:10Dow Jones NewsSeres Therapeutics Shares Rise 15% After Getting FDA Fast-Track Designation for Infection TreatmentNASDAQ:MCRBSeres Therapeutics Inc
09/01/202413:00Business WireSeres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155NASDAQ:MCRBSeres Therapeutics Inc
04/01/202422:00Business WireSeres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:MCRBSeres Therapeutics Inc
08/12/202301:46Business WireSeres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023NASDAQ:MCRBSeres Therapeutics Inc
28/11/202315:18Business WireSeres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ETNASDAQ:MCRBSeres Therapeutics Inc
28/11/202301:01PR Newswire (US)Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science LeadersNASDAQ:MCRBSeres Therapeutics Inc
21/11/202312:00PR Newswire (US)Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of GeneticsNASDAQ:MCRBSeres Therapeutics Inc
02/11/202312:00Business WireSeres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 MillionNASDAQ:MCRBSeres Therapeutics Inc
01/11/202315:30PR Newswire (US)Flagship Pioneering Launches Pioneering IntelligenceNASDAQ:MCRBSeres Therapeutics Inc
30/10/202322:30Business WireSeres Therapeutics to Announce Third Quarter 2023 Results on Thursday, November 2, 2023; Host Conference Call and Webcast at 8:00 a.m. ESTNASDAQ:MCRBSeres Therapeutics Inc
12/10/202313:00Business Wire Seres Therapeutics to Highlight VOWST™ Data at IDWeekNASDAQ:MCRBSeres Therapeutics Inc
11/09/202312:30PR Newswire (US)Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development OfficerNASDAQ:MCRBSeres Therapeutics Inc
07/09/202316:00Business WireSeres Therapeutics to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceNASDAQ:MCRBSeres Therapeutics Inc
29/08/202315:00PR Newswire (US)Invaio achieves first registration for citrus greening solution featuring Trecise™ technologyNASDAQ:MCRBSeres Therapeutics Inc
16/08/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MCRBSeres Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:MCRB

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENEL
Enel
BIT
TIT
Telecom Italia
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
STMMI
ST Microelectronics
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
TEN
Tenaris
BIT
RACE
Ferrari NV
BIT
SPM
Saipem
BIT
BAMI
Banco BPM
BIT
PRY
Prysmian
BIT
BPE
Bper Banca
BIT
TITR
Telecom Italia
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network